OmniAb Inc
OABI1.970USD
+0.060+3.14%
交易中 （美東）報價延遲15分鐘
240.61M總市值
虧損本益比TTM
關於 OmniAb Inc 公司
OmniAb, Inc. 提供的發現平臺爲製藥行業合作伙伴提供多種抗體庫和高通量篩選技術，從而發現下一代療法。OmniAb 平臺是轉基因動物的生物智能 (BI)，包括 OmniRat、OmniChicken 和 OmniMouse，這些動物經過基因改造，可產生具有人類序列的抗體，以促進人類治療候選藥物的開發。該公司的 OmniFlic（轉基因大鼠）和 OmniClic（轉基因雞）通過通用輕鏈方法滿足行業對雙特異性抗體應用的需求，而 OmniTaur 具有針對複雜靶標的牛抗體的結構屬性。該公司的 OmniChicken 和 OmniClic 在進化上遙遠的雞宿主環境中提供親和力成熟的抗體，可將多種抗體組庫遞送至保守的治療靶抗原。
公司簡介
公司代碼OABI
公司名稱OmniAb Inc
上市日期Oct 09, 2020
CEOMr. Matthew William (Matt) Foehr
員工數量114
證券類型Ordinary Share
年結日Oct 09
公司地址5980 Horton Street
城市EMERYVILLE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94608
電話15102507800
網址https://www.omniab.com/
公司代碼OABI
上市日期Oct 09, 2020
CEOMr. Matthew William (Matt) Foehr
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
股東統計
更新時間: 7月25日 週五
更新時間: 7月25日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Avista Capital Holdings, LP
12.93%
Janus Henderson Investors
6.59%
Whitefort Capital Management, LP
5.98%
BlackRock Institutional Trust Company, N.A.
5.28%
Ash X LP
4.43%
Other
64.80%
持股股東
持股股東
佔比
Avista Capital Holdings, LP
12.93%
Janus Henderson Investors
6.59%
Whitefort Capital Management, LP
5.98%
BlackRock Institutional Trust Company, N.A.
5.28%
Ash X LP
4.43%
Other
64.80%
股東類型
持股股東
佔比
Investment Advisor
21.12%
Investment Advisor/Hedge Fund
18.89%
Private Equity
12.93%
Hedge Fund
10.53%
Individual Investor
6.24%
Corporation
5.31%
Research Firm
0.93%
Pension Fund
0.15%
Bank and Trust
0.09%
Other
23.80%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
347
93.30M
76.27%
-5.04M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
2023Q1
319
89.47M
77.82%
-24.53M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Avista Capital Holdings, LP
15.82M
12.93%
--
--
Sep 30, 2024
Janus Henderson Investors
8.06M
6.59%
+97.91K
+1.23%
Mar 31, 2025
Whitefort Capital Management, LP
7.31M
5.98%
+3.40M
+86.81%
May 30, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
5.28%
+62.83K
+0.98%
Mar 31, 2025
Ash X LP
1.09M
0.89%
+1.09M
--
Jun 12, 2025
The Vanguard Group, Inc.
5.18M
4.23%
+142.26K
+2.82%
Mar 31, 2025
Macquarie Investment Management
4.42M
3.62%
+122.07K
+2.84%
Mar 31, 2025
Foehr (Matthew W)
3.80M
3.1%
-13.61K
-0.36%
Apr 23, 2025
Dimensional Fund Advisors, L.P.
3.13M
2.56%
+106.04K
+3.50%
Mar 31, 2025
Higgins (John L)
2.85M
2.33%
+20.00K
+0.71%
Jun 17, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
查看更多
iShares Micro-Cap ETF
佔比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
